Showing 2634 results
- https://www.novartis.com/news/media-releases/novartis-completes-subsequent-offering-period-tender-offer-advanced-accelerator-applications-saBasel, February 1, 2018 - Novartis AG (NYSE: NVS) today announced the completion of the subsequent offering period of the tender offer by its subsidiary, Novartis Groupe France S.A., to purchase all…
- https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-updated-analysis-from-eliana-trial-showing-longer-term-durable-remissions-kymriahtm-children-young-adults-rr-allAnalysis of 75 patients with median follow-up of more than a year demonstrated an overall remission rate of 81% Event-free survival and overall survival at six months were 73% and 90%, with…
- https://www.novartis.com/news/media-releases/advanced-accelerator-applications-receives-fda-approval-lutathera-treatment-gastroenteropancreatic-neuroendocrine-tumorsLutathera marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT) Advanced Accelerator Applications is a newly established subsidiary of Novartis Lutathera…
- https://www.novartis.com/news/media-releases/novartis-exclusively-licenses-first-ophthalmology-gene-therapy-all-markets-outside-us-milestone-patients-rare-inherited-vision-lossNovartis enters into a licensing and supply agreement to develop, register and commercialize investigational gene therapy voretigene neparvovec outside the US; Spark Therapeutics retains US rights…
- https://www.novartis.com/news/media-releases/novartis-delivered-good-operational-performance-and-landmark-innovation-2017-entering-our-next-growth-phaseFull year sales grew 2% (cc, +1% USD) as strong performance of our growth drivers, including Cosentyx and Entresto, more than offset Gleevec/Glivec generic erosion: Cosentyx grew to USD 2.1…
- https://www.novartis.com/news/media-releases/novartis-enregistre-en-2017-une-belle-performance-operationnelle-et-des-innovations-majeures-entrant-ainsi-dans-une-nouvelle-phase-de-croissanceHausse de 2% (tcc, +1% USD) des ventes sur l'exercice complet, car l'excellente performance de nos moteurs de croissance, notamment Cosentyx et Entresto, a plus que compensé l'érosion due aux…
- https://www.novartis.com/news/media-releases/novartis-erzielt-2017-eine-gute-operative-performance-sowie-wegweisende-innovationen-und-ist-gut-gerustet-fur-die-nachste-wachstumsphaseDer Umsatz steigt im Geschäftsjahr um 2% (kWk, +1% USD), wobei die starke Performance unserer Wachstumstreiber, wie Cosentyx und Entresto, die Einbussen durch Generika bei Glivec/Gleevec mehr als…
- https://www.novartis.com/news/media-releases/novartis-renews-commitment-malaria-elimination-investing-usd-100-million-research-and-develop-next-generation-antimalarialsCompany to invest more than USD 100 million to advance research and development of new antimalarials over the next five years Commitment includes expanding access to pediatric antimalarials and…
- https://www.novartis.com/news/media-releases/novartis-bekraftigt-engagement-zur-eliminierung-von-malaria-und-investiert-usd-100-millionen-die-erforschung-und-entwicklung-der-nachsten-generation-von-malariamedikamentenDas Unternehmen investiert in den kommenden fünf Jahren über USD 100 Millionen, um die Erforschung und Entwicklung neuer Malariamedikamente voranzutreiben Das Engagement beinhaltet einen Ausbau…
- https://www.novartis.com/news/media-releases/novartis-renouvelle-son-engagement-afin-deliminer-le-paludisme-en-investissant-100-millions-de-dollars-dans-la-recherche-et-le-developpement-dantipaludiques-de-nouvelle-generationL'entreprise s'apprête à investir plus de 100 millions de dollars afin de faire progresser la recherche et le développement de nouveaux antipaludiques au cours des cinq prochaines années L'…
Pagination
- ‹ Previous page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- …
- 264
- › Next page